Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC

被引：2
|
作者：
Jin, Y. [1 ,4 ]
Han, Y. [2 ]
Zhang, L. [3 ]
Jin, Y. [1 ,4 ]
Sun, H. [5 ]
机构：
[1] UESTC, Dept Gastrointestinal Surg, Affiliated Canc Hosp, Sch Med,Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
[2] Southwest Med Univ, Dept Med Oncol, Affiliated Hosp, Luzhou, Peoples R China
[3] Chongqing Univ, Dept Med Oncol, Three Gorges Hosp, Chongqing, Peoples R China
[4] UESTC, Dept Med Oncol, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China
[5] Chongqing Univ, Dept Gastrointestinal Surg, Canc Hosp, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.540
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
402P
引用
收藏
页码：S720 / S721
页数：2
相关论文
共 50 条
  • [1] Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 137 - 137
  • [2] Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single-arm, multicenter, phase II clinical trial-Update results from ALTER-C001
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15566 - E15566
  • [4] ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan Jin
    Zhang Li
    Jin Yongdong
    Han Yunwei
    Sun Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial
    Jin, Y.
    Han, Y.
    Zhang, L.
    Jin, Y.
    Sun, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S546 - S547
  • [7] Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
    Song, Bo
    Hu, Hai
    Zhang, Li
    Ye, Su-Juan
    Jin, Yong-Dong
    Shang, Chang-Ling
    Zhang, Jun
    Sun, Hao
    Zhang, Ke
    Yi, Bo
    Han, Yun-Wei
    Yan, Jin
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma
    Lin, Haifeng
    Ma, Jie
    Zhuo, Manyun
    Zhang, Chengsheng
    Luo, Jingru
    Zhuang, Xiaohong
    Zeng, Zhiming
    Yang, Lihua
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
    Lin, Haifeng
    Ma, Jie
    Zhuo, Manyun
    Zhang, Chengsheng
    Luo, Jingru
    Zhuang, Xiaohong
    Zeng, Zhiming
    Yang, Lihua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C
    Wu, J.
    Zhou, C.
    Yan, J.
    Han, Z.
    Wang, C.
    Qin, Z.
    Jiang, J.
    Wang, C.
    Tang, X.
    Zhu, L.
    Chen, J.
    Mao, Y.
    Wei, X.
    Shangguan, C.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1533 - S1533
12345